Capstan Launches In Vivo CAR-T Trial Using LNP Technology for Oncology

Published on Spencer Knight via LinkedIn

Capstan Therapeutics has entered Phase 1 trials with CPTX2309, an in vivo CAR-T candidate that uses lipid nanoparticles to deliver anti-CD19 CAR mRNA directly to T cells. This makes Capstan the fifth company globally to bring in vivo CAR-T to clinic, and the second using LNP delivery alongside Myeloid, Interius, Umoja, and EsoBiotec.

To avoid early-phase challenges in the U.S., Capstan moved its trial site to Australia for faster approvals and easier recruitment. Spencer Knight recommends Australia, China, and the U.K. as ideal regions for early-stage cell therapy trials due to favorable infrastructure and regulatory frameworks.

Read the full post on LinkedIn:

👉 Spencer Knight: In Vivo CAR T: The Future of Cell Therapy is Now

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.